Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast pharmacokinetics in Japanese healthy males
NCT06139302Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 144 hours and Maximum Measured Concentration of Nerandomilast in Plasma at 144 hours. Started Dec 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT06139302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139302.